SequelSEC

KIORA PHARMACEUTICALS INC KPRX

Pharmaceutical Preparations · CIK 0001372514 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$12.83M
Fiscal year ended 2025-12-31
Free cash flow
-$10.07M
Fiscal year ended 2025-12-31

KIORA PHARMACEUTICALS INC (KPRX) reported revenue of $0 and net income of -$10.84M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from KIORA PHARMACEUTICALS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

KIORA PHARMACEUTICALS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$12.83M
Net income-$10.84M
Research & development$10.78M
Weighted-average diluted sharesUnavailable
Pretax income-$12.12M
Income tax expense-$1.28M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$5.75M
Selling & marketingUnavailable

Balance

KIORA PHARMACEUTICALS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$8.70M
Total assets$24.25M
Current assets$21.75M
Total liabilities$8.13M
Current liabilities$3.63M
Total equity incl. NCI$16.13M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$1.52M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.06M

Cash flow

KIORA PHARMACEUTICALS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$9.96M
Capital expenditures$110.79K
Investing cash flow$14.43M
Financing cash flow$265.66K
Net change in cash$4.90M
Stock-based compensation$900.24K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$24.80K

Derived

KIORA PHARMACEUTICALS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flow-$10.07M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio5.99x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KPRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.